| Document |
Document Title |
|
WO/2022/071772A1 |
Provided are: a compound of chemical formula 1, having protein kinase inhibitory activity; a stereoisomer thereof or a pharmaceutically acceptable salt thereof; and a use thereof.
|
|
WO/2022/072741A1 |
The present invention relates to novel compounds of formula (la), to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/ TAZ-TEAD transcription, yet more in pa...
|
|
WO/2022/071777A1 |
The present invention relates to a medicinal use of compounds having inhibitory activity against pendrin, and provides a compound represented by chemical formula 1 or 2, below, an E- or Z-isomer thereof, an optical isomer thereof, a prec...
|
|
WO/2022/068917A1 |
Provided is a compound as an Akt kinase inhibitor. The present invention specifically relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition contain...
|
|
WO/2022/063205A1 |
An aryl formamide compound, a preparation method for same, and medicinal uses thereof. Specifically, related are a compound as represented by formula (I), a preparation method therefor, a pharmaceutical composition containing the compoun...
|
|
WO/2022/064459A1 |
The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salts thereof, a composition comprising the compound, methods of using the compound for the treatment of various disorders associated with HPK1, and...
|
|
WO/2022/031701A9 |
Described herein are solid forms of N-(4-fluoro-5-(((2S,4R)-4-((6-methoxypyrimidin-4-yl)oxy)-2-m
ethylpyrrolidin-l-yl)methyl)thiazol-2-yl)acetamide, compound (I): (I) and the process of making said solid forms of compound (I). The presen...
|
|
WO/2022/066917A1 |
Disclosed are compounds of Formula (1) and pharmaceutically acceptable salts thereof, wherein L1, R1, R2, R3, R4, R6, R7, R8, R9 and X5 are defined in the specification. This disclosure also relates to materials and methods for preparing...
|
|
WO/2022/063153A1 |
Provided are compounds of Formula (I) or (II) and related compositions and methods for their use as inhibitors of alpha-kinase 1 (ALPK1).
|
|
WO/2022/062597A1 |
A thermally activated delayed fluorescence material and the use thereof. The thermally activated delayed fluorescence material has a diquinoxaline structure, is new in structure, has good photoelectric properties, and is suitable as a li...
|
|
WO/2022/063152A1 |
Provided are compounds of Formula I, compositions and methods for their use as inhibitors of alpha-kinase 1 (ALPK1).
|
|
WO/2022/063858A1 |
The invention provides immunomodulatory compounds, adjuvant compositions comprising thereof, immunogenic compositions comprising thereof and uses of immunomodulatory compounds as adjuvants in vaccination, for increasing the immune respon...
|
|
WO/2022/057672A1 |
Disclosed in the present invention is an FXR (farnesoid X receptor) small molecule agonist and a preparation method therefor, the structure thereof being as shown in formula I. The definitions of the substituent groups are as set forth i...
|
|
WO/2022/057387A1 |
A 3-(3-Aryl/heteroaryl-4-thiazolinone)-N-aryl/heterocyclic benzamide compound, or a pharmaceutically-acceptable salt thereof, and a preparation method therefor. The compound type or a pharmaceutical composition thereof can be used to tre...
|
|
WO/2022/057842A1 |
Method for preparation of substituted pyrimidine piperazine compounds, as well as intermediate compounds used in the method. The preparation method provided herein has the advantages of cheap and easily available raw materials, mild cond...
|
|
WO/2022/058878A1 |
The present invention relates to a compound of formula (I), Formula (I), wherein, R1, R1a, R2, W, R3, R4, R5, A, R6, R7 and R8 are as defined in the detailed description and to a process for preparing the compound of formula (I). The pre...
|
|
WO/2022/060812A1 |
This disclosure is drawn to substituted pyridine compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing neurological diseases.
|
|
WO/2022/061348A1 |
Provided herein are SOS1 protein degraders, for example, a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of ...
|
|
WO/2022/053659A2 |
The use of a heterocyclic compound of the general formula (I) with the following definitions: X S or NR4 with R4 being C1-4-alkyl, R1 C3-12-hydrocarbon residue which can contain 1 to 3 heteroatoms selected from the group consisting of ni...
|
|
WO/2022/053453A1 |
The invention relates to novel compounds of formula (I), wherein A, V, R1 and R2 have the above mentioned meaning, and to their use for controlling animal pests, in particular arthropods and especially insects and arachnids.
|
|
WO/2022/053660A2 |
The use of an N-heterocyclic compound of the general formula (a) or (b) with the following definitions: X1 being S or O, X2 being S or O and at least one of X1 and X2 being S R2 H or C1-4-alkyl, R3 H or C1-4-alkyl R6 and R7 are hydrogen ...
|
|
WO/2022/056447A1 |
Provided herein are compounds and compositions thereof for modulating bis-phosphoglycerate mutase (BPGM) for treating sickle cell disease.
|
|
WO/2022/056068A1 |
The present disclosure relates to compounds that are capable of inhibiting the ENPP1 gene and treating a variety of cardiac conditions. The disclosure further relates to methods of treating or preventing cardiac conditions, such as myoca...
|
|
WO/2022/053541A1 |
The present invention relates to new compounds having appetite-suppressing effects and their uses as a drug for treating diseases and disorders, especially metabolite syndrome.
|
|
WO/2022/056449A1 |
Provided herein are compounds and compositions thereof for modulating bis-phosphoglycerate mutase (BPGM) for treating sickle cell disease.
|
|
WO/2022/056281A1 |
Provided herein are compounds including compounds of formula (I), compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosph...
|
|
WO/2022/053718A1 |
The invention provides a method for labeling a nucleic acid comprising N6-methyl adenine. The method comprises forming an alpha-amino radical on the N6-methyl group of N6mAde, and capturing the alpha-amino radical with a radical acceptor...
|
|
WO/2022/053803A1 |
The present invention relates to the use of compounds of Formula (I) as agrochemicals, preferably herbicides, wherein X, X', X'', R2, F3, R4 and R5 are as defined herein. The invention further relates to agrochemical compositions compris...
|
|
WO/2022/048988A1 |
Compounds of formula (I) wherein the substituents are as defined in claim 1, useful as plant growth regulators and/or seed germination promoters.
|
|
WO/2022/049253A1 |
Substituted N-heteroaryl-N-pyridinylacetamide of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds...
|
|
WO/2022/051326A1 |
Leucine zipper‑bearing kinase (LZK) targeted degraders are disclosed. The compounds have a general formula Q‑L‑Z where Q is an LZK binding moiety, L is a linker, and Z is an E3‑ligase binding moiety. The compounds inhibit LZK act...
|
|
WO/2022/047086A1 |
Compounds according to formula (I) are described wherein R1 is an amino acid or a modified amino acid linked to the compound through a peptide bond, R2 is selected from CN, SO2CH3, NO2, CO2R3, CONHR3, NH2, NMe2 and CF3, and R3 is selecte...
|
|
WO/2022/043491A2 |
Disclosed herein are detectable moieties and detectable conjugates comprising one or more detectable moieties. In some embodiments, the disclosed detectable moieties have a narrow wavelength and are suitable for multiplexing. Also disclo...
|
|
WO/2022/042591A1 |
Provided is a nitrile derivative compound represented by formula (I), a stereoisomer, a deuterated product, a co-crystal, a solvate or a pharmaceutically acceptable salt thereof, wherein each group is as defined in the description. The c...
|
|
WO/2022/047260A1 |
The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, t...
|
|
WO/2022/042613A1 |
Disclosed are a 1H-pyrazol-4-amide derivative having a structure as represented by formula (I), a preparation method therefor, a pharmaceutical composition containing same, the use thereof as an inhibitor for FGFR and a mutation thereof,...
|
|
WO/2022/046861A1 |
Disclosed herein are compounds and compositions having potency in the modulation of Myc family proteins. Such compounds and compositions can be used in the treatment of proliferative diseases, such as cancer, or in the treatment of disea...
|
|
WO/2022/047347A1 |
Provided herein are secretion inhibitors, such as inhibitors of Sec61 for example of Formula (I), methods for their preparation, related pharmaceutical compositions, and method for using the same.
|
|
WO/2022/047315A1 |
The present disclosure is directed to compounds, compositions, formulations and methods of use thereof in the treatment and prevention of ocular conditions including cataract and presbyopia.
|
|
WO/2022/045093A1 |
The present invention relates to a compound represented by formula (I) or (II), a pharmaceutically acceptable salt of the compound, or a solvate of the compound or the pharmaceutically acceptable salt.
|
|
WO/2022/045618A1 |
Provided is a tertiary amine derivative, which effectively absorbs high-energy external light source in a UV region to minimize damage to organic materials inside an organic electroluminescent device, and thus contributes to a substantia...
|
|
WO/2022/040070A1 |
The present invention is directed to bicyclo[4.1 0]heptane pyrrolidine compounds of formula (I) which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential tre...
|
|
WO/2022/038356A1 |
The present invention relates to compounds of Formula (I) that function as LMO2 activity: Formula (I) wherein R1, X1, X2, X3, Q, R2, R3 and R4 are each as defined herein. The present invention also relates to processes for the preparatio...
|
|
WO/2022/040324A1 |
The present disclosure is generally directed to modulators of hydroxysteroid dehydrogenase enzymes useful in the treatment of diseases and disorders modulated by said enzyme and having the Formula (I), Formula (II), or Formula (III).
|
|
WO/2022/038066A1 |
The present invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing these compounds.
|
|
WO/2022/037691A1 |
Provided are an aromatic ring-lactam compound as shown in formula (I), and a preparation method therefor and the use thereof. The aromatic ring-lactam compound has a novel structure, has good inhibitory activity on ERK1/2 kinases, can in...
|
|
WO/2022/037580A1 |
The present invention relates to a crystal of compound X7 hydrochloride of formula (I), a preparation method therefor and the use thereof. A 2θ diffraction angle in the X-ray powder diffraction pattern of the crystal of compound X7 hydr...
|
|
WO/2022/033532A1 |
Provided are an FGFR and a mutation inhibitor thereof, and a preparation method therefor and the use thereof. In particular, provided are an FGFR having a structure of formula (I) and a mutation inhibitor thereof, a preparation method th...
|
|
WO/2022/033420A1 |
The present invention provides a compound as a PAK4 inhibitor having a structure shown in formula I, or a tautomer, mesomer, racemate, enantiomer, diastereomer or a mixture thereof, or a pharmaceutically acceptable hydrate, solvate, or s...
|
|
WO/2022/036080A1 |
The present disclosure relates to compounds of Formula (I) and their prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods of their preparation. The compounds disclosed herein are...
|
